BTK and B-cell chronic lymphocytic leukemia: Based on the high rate of deep responses and long remission durations combined with good tolerability, venetoclax-based combinations with BTK inhibitors or triple combinations are very likely the future of CLL treatment; however, the approaches are still experimental and require more clinical data before adapted in general practice.